A Chinese stock exchange’s first-ever blunt refusal to a biotech’s initial public offering request has raised a red flag to some investors, who have been keeping a close watch on the in-licensing business model widely adopted in the biopharma sector.
While the path of in-licensing offers a shortcut to drug commercialization, it has recently run into opposition from China’s securities regulator due to lack of proprietary rights to innovation, Scrip heard at the annual China BioMed Innovation and Investment Conference (CBIIC) in Suzhou, China, organized by the
